Incyte | INCY - Dochód Netto





Dochód Netto Zmiana Data
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agenus USD -10.63M 74.49M 2025-12
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Exelixis USD 210.47M 34.06M 2026-03
Gilead Sciences USD 2.02B 162M 2026-03
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
MacroGenics USD -36.77M 22.62M 2026-03
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novartis USD 3.16B 747M 2026-03
Novartis USD 3.16B 747M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03